Can eculizumab be an option in traditional treatment-resistant ulcerative colitis? Atypical Hemolitic Uremic Syndrome with Ulcerative Colitis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 4 (2023),
20 September 2023
https://doi.org/10.22037/ghfbb.v16i4.2689
Abstract
Atypical/complement-mediated hemolytic uremic syndrome (A-HUS/CM-HUS) is a hereditary or sporadic disease with thrombotic microangiopathy (TMA). Diarrhea is a trigger that can cause attacks of CM-HUS. Although there are opinions that complement system activation plays a role in intestinal inflammation in patients with inflammatory bowel disease, the association of TMA with inflammatory bowel disease (IBD) has rarely been reported. In our case, a CM-HUS case that developed without an additional triggering factor in the course of ulcerative colitis (UC) was successfully treated with eculizumab, and then UC remission was also achieved. In this context, we would like to point out that the irregularities in the alternative pathway of the complement system may cause clinical findings in extra-renal organs, and the complement system may also play a role in the pathogenesis of inflammatory bowel disease. In addition, we think that our case may guide further studies on the usability of anti-complement therapies in treating patients with IBD who are resistant to conventional treatments.
- Atypical hemolytic uremic syndrome
- eculizumab
- inflammatory bowel disease
- ulcerative colitis
How to Cite
References
Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420.
Chantal L, Véronique Frémeaux-B. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6.
Marina N, Federica M, Giuseppe R. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-633.
Craner GE, Burdick GE. Acute colitis resembling ulcerative colitis in the hemolytic-uremic syndrome. Am J Dig Dis 1976;21:74-76.
Viada Bris JF, Velasco Rodríguez-Belvís M, de Lucas Collantes C, Aparicio López C, Martínez de Azagra A, de Lama Caro-Patón G, et al. Ulcerative colitis and atypical hemolytic-uremic syndrome: an unusual but potentially life-threatening complication. Inflamm Bowel Dis 2019;25:27-28.
Schleinitz N, Faure V, Bernit E, Veit V, Harlé JR, Poullin P, et al. Autoimmune thrombotic thrombocytopenic purpura: a severe complication of inflammatory bowel disease. J Clin Gastroenterol 2003;36:83-4.
Unverdi S, Ceri M, Öztürk M, Akbal E, failure AE-R, 2011 undefined. A patient with Crohn’s disease who presented with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Taylor Fr 2011;33:244-245.
Green H, Harari E, Davidovits M, Dorit B, Alon G, Uzi Gafter et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 2014;36:1119-1121.
Webb TN, Griffiths H, Miyashita Y, Riha B, Ronald J, Michael M et al. Atypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumab. Int J Med Pharm Case Reports 2015;4:105-112.
Øzbay LA. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis. Clin J Gastroenterol 2019;13:344-348.
Viada Bris JF, Velasco Rodríguez-Belvís M, De Lucas Collantes C, Cristina Aparicio López, Amelia Martínez de Azagra, Gema de Lama Caro-Patón et al. Erratum to: ulcerative colitis and atypical hemolytic-uremic syndrome: an unusual but potentially life-threatening complication. Inflamm Bowel Dis 2019;25:151.
Hanna RM, Merin N, Burwick RM, Lama A, Umut S, Beshoy Y et al. Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease. Thromb J 2019;17.
Horváth O, Kelen K, Prohászka Z, Hosszú Á, Szabó AJ, Reusz GS. Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment. Pediatr Nephrol 2021;36:3277-3280.
Ramy MH, Marina B, Andrae V, Ira K, Richard B. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-287.
Halstensen TS, Brandtzaeg P. Local complement activation in inflammatory bowel disease. Immunol Res 1991;10:485-492.
Trent M W, Thiruma V A, Ian A S, Robert C R, David P F, Stephen M T. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003;171:5514-5520.
Kay J, Myriam M, André B, Michael K, Oliver DB, Engelbert G. et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1812-1823.
Sina C, Kemper C, Derer S. The intestinal complement system in inflammatory bowel disease: shaping intestinal barrier function. Semin Immunol 2018;37:66-73.
Jokiranta TS. HUS and atypical HUS. Blood 2017;129:2847-2856.
Peter F Z, Matthew E, Stefan H, Mihály J, Heiko R, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3:0387-0392.
Jian J, Hui W, Melanie K, Huijuan C, Xiaoxia Q, Kenneth MK et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011;7.
David K, Tim G. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-2442.
Tao Z, Jianping L, Shaoshan L, Dachen C, Haitao Z, Caihong Z al. Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome. Am J Nephrol 2016;43:160-169.
Cassandra F, Agnieszka SU. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-1348.
Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-1373.
Jain U, Otley AR, Van Limbergen J, Stadnyk AW. The complement system in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1628-1637.
- Abstract Viewed: 145 times
- PDF Downloaded: 173 times